

RESEARCH

Open Access



Long-term exposure to PGE₂ causes homologous desensitization of receptor-mediated activation of protein kinase A

Ramy Habashy Malty^{1,3}, Andy Hudmon², Jill C. Fehrenbacher³ and Michael R. Vasko^{4*}

Abstract

Background: Acute exposure to prostaglandin E₂ (PGE₂) activates EP receptors in sensory neurons which triggers the cAMP-dependent protein kinase A (PKA) signaling cascade resulting in enhanced excitability of the neurons. With long-term exposure to PGE₂, however, the activation of PKA does not appear to mediate persistent PGE₂-induced sensitization. Consequently, we examined whether homologous desensitization of PGE₂-mediated PKA activation occurs after long-term exposure of isolated sensory neurons to the eicosanoid.

Methods: Sensory neuronal cultures were harvested from the dorsal root ganglia of adult male Sprague-Dawley rats. The cultures were pretreated with vehicle or PGE₂ and used to examine signaling mechanisms mediating acute versus persistent sensitization by exposure to the eicosanoid using enhanced capsaicin-evoked release of immunoreactive calcitonin gene-related peptide (iCGRP) as an endpoint. Neuronal cultures chronically exposed to vehicle or PGE₂ also were used to study the ability of the eicosanoid and other agonists to activate PKA and whether long-term exposure to the prostanoid alters expression of EP receptor subtypes.

Results: Acute exposure to 1 μM PGE₂ augments the capsaicin-evoked release of iCGRP, and this effect is blocked by the PKA inhibitor H-89. After 5 days of exposure to 1 μM PGE₂, administration of the eicosanoid still augments evoked release of iCGRP, but the effect is not attenuated by inhibition of PKA or by inhibition of PI3 kinases. The sensitizing actions of PGE₂ after acute and long-term exposure were attenuated by EP2, EP3, and EP4 receptor antagonists, but not by an EP1 antagonist. Exposing neuronal cultures to 1 μM PGE₂ for 12 h to 5 days blocks the ability of PGE₂ to activate PKA. The offset of the desensitization occurs within 24 h of removal of PGE₂ from the cultures. Long-term exposure to PGE₂ also results in desensitization of the ability of a selective EP4 receptor agonist, L902688 to activate PKA, but does not alter the ability of cholera toxin, forskolin, or a stable analog of prostacyclin to activate PKA.

Conclusions: Long-term exposure to PGE₂ results in homologous desensitization of EP4 receptor activation of PKA, but not to neuronal sensitization suggesting that activation of PKA does not mediate PGE₂-induced sensitization after chronic exposure to the eicosanoid.

* Correspondence: vaskom@iupui.edu

⁴Department of Pharmacology and Toxicology, Indiana University School of Medicine, 635 Barnhill Dr., A449, Indianapolis, IN 46202, USA
Full list of author information is available at the end of the article

Background

Prostaglandin E₂ (PGE₂) is a critical inflammatory mediator that contributes to acute and chronic pain by directly altering the sensitivity of sensory neurons to noxious and non-noxious stimuli [1, 2]. This eicosanoid is produced and released in the periphery by acute tissue injury, and its production is sustained during chronic inflammation [3–5]. Acute sensitization of sensory neurons by PGE₂ occurs through activation of EP receptors that couple to the G_{αs}/3',5'-cyclic adenosine monophosphate (cAMP) signaling pathway [6]. Acute exposure to PGE₂ increases the production of cAMP in sensory neurons [7, 8], and inhibition of protein kinase A (PKA) attenuates prostaglandin-induced hyperalgesia [9] and prostaglandin-induced increases in sodium currents [10, 11] and TRPV1 channel activity [12].

The signaling for chronic prostaglandin-mediated sensitization has been historically quite puzzling, since it is well established that chronic exposure to agonists can desensitize G-protein-coupled receptors (GPCRs) [13, 14]. However, an important characteristic of prostaglandin-induced hypersensitivity is that it does not downregulate with long-term exposure to the eicosanoid. For example, in patients with chronic inflammatory conditions, drugs that prevent the synthesis of prostaglandins (non-steroidal anti-inflammatory drugs, NSAIDs) are effective in reducing both acute and chronic hypersensitivity [15–17], suggesting that prostaglandins maintain their ability to sensitize sensory neurons through a mechanism that is not subject to classical GPCR downregulation. In animal models of inflammation or in animals chronically exposed to PGE₂, the ability of the eicosanoid to enhance nociception does not diminish, but subsequent administration of PGE₂ results in a stronger and more prolonged hyperalgesia [18–20]. This phenomenon, termed “hyperalgesic priming” [21], can be modeled in isolated sensory neurons where acute exposure to PGE₂ sensitizes neurons to various stimuli [1, 7, 22] and, like their *in vivo* counterparts, the sensitizing actions of eicosanoids are not diminished by chronic exposure [23, 24].

Although the cellular mechanisms that account for persistent sensitization of sensory neurons by PGE₂ are not known, one potential explanation for maintaining sensitization is through effector switching. For example, after an inflammatory insult, which increases production of prostaglandins and other inflammatory mediators, hyperalgesia induced by subsequent injection of PGE₂ is not attenuated by inhibiting PKA but is blocked by inhibitors of other signaling effectors [20, 25]. After 14 daily injections of PGE₂ into the rat hindpaw, hyperalgesia-induced by PGE₂ injection is attenuated by PKA and protein kinase C inhibitors, not just by inhibiting PKA [18]. In sensory neurons from normal animals, the ability of PGE₂ to augment ATP-induced current is blocked by PKA inhibitors, whereas in neurons from inflamed rats,

the PGE₂ effect is abolished only after inhibition of both PKA and protein kinase C (PKC) [26]. Furthermore, when isolated sensory neurons are maintained in culture with the inflammatory mediator, nerve growth factor (NGF), the ability of PGE₂ to sensitize the neurons is not blocked by inhibition of PKA, whereas in neurons grown without NGF, PKA inhibition is effective [27]. These data suggest that PKA is not the major effector of persistent PGE₂-induced sensitization of sensory neurons.

To date, there are few, if any, studies that directly examine whether chronic exposure to PGE₂ downregulates the activation of PKA and, if so, whether this downregulation is specific for PGE₂-induced activation. Consequently, using sensory neuronal cultures, we examined whether long-term exposure to PGE₂ causes a loss in the ability of the eicosanoid to activate PKA. Our results show that chronic exposure of sensory neuronal cultures to PGE₂ or an EP4 receptor agonist results in a complete but reversible loss in the ability of PGE₂ to activate PKA. Furthermore, both acute sensitization and that which is observed after long-term exposure to PGE₂ show the same profile of EP receptor activation suggesting that the downregulation is not secondary to alterations in EP receptor expression or function. This functional downregulation of PKA is homologous since activation of PKA by carbaprostacyclin, forskolin, or cholera toxin is not altered by chronic exposure to PGE₂.

Methods

Materials

Fetal bovine serum, F-12 media, glutamine, penicillin-streptomycin, and fungizone were obtained from Invitrogen, Carlsbad, CA, whereas Normocin was purchased from InvivoGen, San Diego, CA. The small molecule PKA inhibitor H-89, the PKA pseudosubstrate inhibitor fragment 5-24 (PKI 5-24), Kemptide, poly-D-lysine, laminin, collagenase, 5-fluoro-2'-deoxyuridine, uridine, capsaicin, 1-methyl-2-pyrrolidinone (MPL), cholera toxin (CTX), TG4-155, and other routine chemicals were purchased from Sigma-Aldrich, St. Louis, MO. PGE₂, carbaprostacyclin (cPGL₂), L902688, ONO-8711, ONO-AE3-208, rabbit polyclonal antibodies for EP receptors, and cAMP enzyme immunoassay kits were purchased from Cayman Chemicals, Ann Arbor MI. L-798,106 was purchased from Santa Cruz, Dallas, TX. 3-isobutyl-1-methylxanthine (IBMX) and rat calcitonin gene-related peptide (CGRP) were obtained from Tocris Bioscience, Minneapolis, MN, and (Tyr27)-α-CGRP (27–37) was acquired from Bachem, Torrance, CA. [³²P]-ATP was purchased from PerkinElmer, Waltham, MA. Protease inhibitor cocktail Set III, EDTA-free, and phosphatase inhibitor cocktail set I were obtained from EMD Millipore, Darmstadt, Germany. LI-COR blocking buffer, TO-PRO-3, and Rockford secondary antibodies were obtained from LI-COR Biosciences, Lincoln, NE. Prestained protein size markers, precast

SDS-PAGE gels, iScript reverse transcription kits, and PVDF membranes were obtained from BioRad, Hercules, CA. RNA STAT-60 was purchased from Tel-test, Inc., Friendswood, TX. Normal donkey serum was from Jackson ImmunoResearch Laboratories, West Grove, PA. NGF was purchased from Envigo, Indianapolis, IN. PGE₂, cPGI₂, L902688, forskolin, and capsaicin were initially dissolved in MPL and then diluted to the desired concentration with phosphate-buffered saline (PBS). Cholera toxin was dissolved in a buffer consisting of 0.05 M Tris buffer, pH 7.5, 0.2 M NaCl, 0.003 M NaN₃, and 0.001 M sodium EDTA as per Sigma-Aldrich product information. Other drugs were diluted in PBS. The Animal Care and Use Committee at Indiana University School of Medicine, Indianapolis, IN, approved all procedures used in these studies.

Cell culture

Sensory neuronal cultures were prepared as described previously with minor modifications [28]. Male Sprague-Dawley rats weighing approximately 145 g (Harlan, Indianapolis, IN) were euthanized by CO₂ asphyxiation, and the dorsal root ganglia (DRG) were dissected from the entire spinal column and then incubated in F-12 media containing collagenase (1.25 mg/ml) for 1 hour at 37 °C. The collagenase-containing F-12 media was aspirated and replaced with fresh F-12 containing Normocin, and the DRG were mechanically dissociated using a fire-polished glass pipette. Cell culture wells were pre-coated with poly-D-lysine and laminin, and approximately 15,000 cells were plated into each well of 24-well culture plates, approximately 30,000 cells were plated into each well of 12-well culture plates, or approximately 60,000 cells were plated into each well of 6-well cultures plates. Cells were maintained in F-12 media supplemented with 10 % fetal bovine serum, 2 mM glutamine, 100 µg/ml Normocin, 50 µg/ml penicillin, 50 µg/ml streptomycin, 50 µM 5-fluoro-2'-deoxyuridine and 150 µM uridine in saturated humidity, and 3 % CO₂ incubator at 37 °C. Cultures were grown in the absence or presence of 30 ng/ml exogenously added NGF, as indicated, and the media was changed every other day. For experiments involving long-term exposure to PGE₂, media with fresh PGE₂ was changed every 24 h.

Neuropeptide release

For release experiments, neuronal cultures grown for 8–12 days were washed with HEPES buffer (25 mM HEPES, 135 mM NaCl, 3.5 mM KCl, 2.5 mM CaCl₂, 1 mM MgCl₂, 3.3 mM D-glucose, and 0.1 % bovine serum albumin, pH 7.4) at 37 °C. Cultures were incubated for 10 min in 0.4 ml HEPES buffer in the presence and absence of vehicle or drugs to determine resting release and then for 10 min in 0.4 ml of HEPES buffer

containing 30 nM capsaicin in the presence or absence of vehicle or drugs to stimulate peptide release. A third incubation with HEPES buffer alone for 10 min was performed to confirm the return to resting release, which occurs in all experiments. At the end of the release protocol, the cells were hypotonically lysed by incubation for 10 min in 0.4 ml of 0.1 M HCl to extract total remaining CGRP in the culture. Release and content samples were aliquoted and assayed for immunoreactive CGRP (iCGRP) by radioimmunoassay as previously described [29]. Release data are presented as percent of total iCGRP content/10 min.

Measurement of PKA activity

On the day of the experiment, the F-12 media in the cultures was replaced with drug-free fresh media and maintained for 20 min in the CO₂ incubator. The cultures were then exposed to different drug treatments at 37 °C for 10 min, followed by two washes in ice-cold PBS. Cultures were lysed in 250 µl of ice-cold lysis buffer that contained β-glycerophosphate 25 mM, EGTA 1.25 mM, MgCl₂ 10 mM, dithiothreitol 1 mM, ×2 protease inhibitors cocktail set III, NaCl 100 mM, and 1 % Triton-X 100. Cells were scraped, and the buffer was snap-frozen in liquid nitrogen, stored at –80 °C, and assayed within 24 h. After thawing, cell lysates were briefly sonicated followed by centrifugation at 16,100×g for 30 min at 4 °C. For each sample, 10 µl of the supernatant was added to 40 µl of the PKA activity assay buffer containing β-glycerophosphate 25 mM, EGTA 1.25 mM, MgCl₂ 10 mM, NaCl 100 mM, dithiothreitol 0.5 mM, ×2 phosphatase inhibitor cocktail set I, ATP 100 µM, [γP³²]-ATP (3 µCi/40 µl), and Kemptide 10 µM. The reaction was incubated at 30 °C for 5 min. At the end of the 5 min incubation, 20 µl of this reaction mixture was spotted on P81 filter paper discs (Whatman, GE Healthcare Life Sciences) and washed five times (5 min per wash) in 15 mM phosphoric acid. The bound radioactivity was measured using Cerenkov counting in a scintillation counter. PKA activity was measured as a function of incorporation of radioactive phosphate into Kemptide, a peptide that is selectively phosphorylated by PKA [30, 31]. Under these assay conditions, PKA-induced phosphorylation exhibits a linear relationship ($r^2 = 0.99$) over time for up to 10 min (data not shown) indicating that the substrates, ATP and Kemptide, are not limiting during the 5 min of incubation used in our studies. PKA activity was measured in the presence or absence of the selective pseudosubstrate inhibitor, PKI 5-24 (5 µM) and the difference represented as selective PKA activity. The PKA data are calculated as the ratio of the treatment-activated PKA minus nonspecific activity (determined in the presence of PKI 5-24) divided by the maximum PKA activity (using 10 µM cAMP) minus its nonspecific activity (determined in the presence of cAMP and PKI 5-24).

Measure of cAMP

Growth medium was aspirated from the culture dishes, and cells were washed twice with 0.4 ml of HEPES buffer containing 2 mM IBMX. After washing, cells were incubated in 0.4 ml HEPES buffer containing IBMX for 20 min in the absence or presence of vehicle, 1 μ M PGE₂, or 1 μ M forskolin. The HEPES buffer was aspirated, and the cells were scraped into 300 μ l 0.1 N HCl, boiled for 5 min, and centrifuged at 1200 \times g for 15 min. The supernatant was decanted, frozen, and lyophilized. Samples were resuspended, and immunoreactive cAMP was assayed using enzyme immunoassay kits from Cayman Chemical according to kit instructions. Data were expressed as pmol of cAMP per well.

RNA isolation and quantitative real-time RT-PCR

To extract RNA, the growth medium was removed and RNA STAT-60 was added directly to the wells. The cell lysate was transferred to a RNase- and DNase-free 1.5 ml Eppendorf tube and allowed to sit for 5 min at room temperature before the addition of chloroform (0.2 ml/1 ml RNA STAT-60). The samples were vortexed briefly, stored at room temperature for 5 min, and centrifuged at 12,000 \times g for 15 min at 4 °C. The aqueous layer containing RNA was transferred to a fresh RNase- and DNase-free Eppendorf tube, and the RNA was precipitated overnight at room temperature by the addition of 0.5 ml isopropanol. The RNA precipitate was pelleted by centrifugation at 12,000 \times g for 15 min at 4 °C. The supernatant was removed, and the remaining RNA pellet was washed with 1 ml of 75 % ethanol. The mixture was centrifuged at 7500 \times g for 10 min at 4 °C, the ethanol removed, and the pellet allowed to dry until no moisture was evident in the tube. The RNA pellet was resuspended in 20 μ l of water treated with diethyl pyrocarbonate (DEPC water), and a 1/20 dilution of the RNA was quantitated using a BioRad SmartSpec 3000.

Following RNA isolation, approximately 1.5 μ g of RNA product, 2 units of DNase I, and reaction buffer (20 mM Tris-HCl, 2 mM MgCl₂, 50 mM KCl) were incubated at room temperature for 15 min. The DNase was inactivated by incubation at 65 °C in the presence of 2.5 mM EDTA. Approximately 1.0 μ g of total RNA was reverse transcribed using the iScript cDNA synthesis kit. The reaction mix included 15 μ l of RNA (1.0 μ g), 4 μ l of iScript Reaction mix, and 1 μ l of iScript Reverse Transcriptase. The reaction was incubated at 25 °C for 5 min, followed by 42 °C for 30 min, and 85 °C for 5 min. Reverse transcription products were diluted and real-time PCR performed on an ABI Prism 7700 Sequence Detector, using SYBR Green Ampli-taq Master Mix (Thermo Fisher Scientific). The primers were designed to be selective for each of the PGE₂ receptor subtypes and splice variants, and for GAPDH, which was used as an endogenous control. Primer sequences were as follows: EP1F: AACAGGCGGTAACGGCACAT, EP1R:

CGCAGTCTGCCTGCAACCT (NM_013100; amplicon size 110 bp); EP3CF: TCGCTGAACCAGATCTTGGAT, EP3CR: CTGGAGACAGCGTTTGCTACC (D16443; amplicon size 91 bp); EP4F: CCCTCTATACCTGC-CAGACC, EP4R: CATGCGTACCTGGAAGCAAA (NM_032076; amplicon size 68 bp); and GAPDH: TTCA ATGGCACAGTCAAGGC, GAPDHR: TCCTGGAAGA TGGTGATGGG (X02231; amplicon size 70 bp). Amplification was performed using universal PCR parameters. After completion of 40 cycles, the temperature was ramped from 60 to 95 °C over 20 min to establish a dissociation curve in each PCR experiment to verify that the fluorescence signal was due to a single amplicon amplification.

The relative standard curve method was used to quantify relative changes in messenger RNA (mRNA) expression. Standard curves from 1- to 100-fold dilutions of the experimental control starting cDNA were prepared for both the genes of interest and for GAPDH. For each experimental sample (two replicates of two different dilutions), the amount of the gene of interest and GAPDH was determined by the appropriate standard curve. These concentrations were corrected for dilution and normalized to the amount of cDNA in the vehicle-treated control group.

Li-Cor quantitative immunohistochemistry

Neuronal cultures grown in 24-well culture plates were treated as indicated. Immediately after treatment, the buffer containing drugs was aspirated and 4 % formalin in PBS was placed on the cells for 20 min. The fixed cells were then rinsed five times with PBS containing 0.5 % Triton X-100 for 5 min each rinse. Cells were treated with Triton X-100 and then blocked using a 1:1 dilution of the Li-Cor blocking buffer in PBS for at least 2 h. Primary antibodies to the EP1, EP3, and EP4 receptors were diluted in 50 % Li-Cor blocking buffer solution in PBS at 1:50–1:250. Cells were incubated in primary antibody overnight and then rinsed five times with PBS containing 0.5 % Tween-20. Some wells of cells were not incubated with primary antibody to determine the nonspecific actions of the secondary antibody, i.e., background staining. The secondary antibody, Rockford goat anti-rabbit antibody, conjugated to IRDye™ 800CW was diluted in the 1:1 Li-Cor blocking buffer solution in PBS at 1:800. TO-PRO-3, a nucleic acid stain that emits signal detected on the 700 channel of the infrared scanner, was added to the secondary antibody at a concentration of 1:2000. Cells were incubated in the secondary antibody and TO-PRO-3 for 2 h. This portion of the experiment was performed in the dark, as the infrared dyes can photobleach in a manner similar to fluorescent dyes. The secondary antibody was then removed, and the cells were washed five times with PBS containing 0.5 % Tween-20. The plates of cells were allowed to air-dry and were scanned for infrared signal.

The plates were scanned using the Odyssey Imager infrared scanner. The scan intensity was set at 5 for both the 700- and 800-nm channels, and the scan quality was set at a resolution of 169 μm for medium quality scans. Both the 700 channel and the 800 channel were scanned simultaneously. Background signal was subtracted from the wells that were incubated with primary antibody. The signal intensity at the 800 channel (EP signal) was normalized to the most intense EP well for each experimental group to control for differences in staining intensities between different plates. The percent of maximum EP intensity was then divided by the signal at the 700 channel (nucleic acid signal) to correct for possible differences in cell density. Data were expressed as percent of the maximal EP immunoreactivity: TO-PRO-3 immunoreactivity.

Data analysis

Data are expressed as mean \pm the standard error of the mean (SEM) for at least three independent experiments from separate harvests. Protein kinase A activity data were analyzed using one-way ANOVA followed by Bonferroni's post hoc test or using Student's *t* test as indicated. For cAMP content, mRNA, and protein expression, a paired Student *t* test was used to determine significant differences between control and treated wells. A *p* value of <0.05 was considered statistically significant in all experiments.

Results

Prostaglandin E₂ and agents that increase production of cAMP augment PKA activity in sensory neuronal culture

Previous studies have shown that exposing sensory neurons in culture to PGE₂ or prostaglandin I₂ (PGI₂) increases the production of cAMP [6, 7]. Furthermore, inhibitors of PKA attenuate the acute sensitizing actions of PGE₂ suggesting that sensitization is mediated by activation of PKA [11, 12, 26, 32]. Because cAMP has multiple downstream effectors, we measured whether exposing sensory neuronal cultures to increasing concentrations of PGE₂ would directly increase PKA activity (see the "Methods" section for details). When sensory neuronal cultures were exposed to PGE₂ for 10 min and PKA activity determined in cell lysates, treatment with PGE₂ resulted in a concentration-dependent increase in PKA activity (Fig. 1a). The relationship between the log concentration of PGE₂ and PGE₂-induced PKA activity was fit to a sigmoidal curve with a correlation coefficient of 0.95 and an EC₅₀ of 0.8 μM . The normalized PKA activity increased from 0.06 ± 0.01 for cultures treated with 0.1 μM PGE₂ to 0.78 ± 0.10 for cultures exposed to 10 μM PGE₂. Concentrations of 0.3, 1, 3, and 10 μM PGE₂ all produced a significant increase in PKA activity compared to vehicle (Fig. 1a).

Previously, we showed that the acute sensitizing actions of PGE₂ on sensory neurons are mediated, in part, by activation of the EP4 receptors, which are coupled to G_{αs} [6].

Furthermore, increasing cAMP production via exposure of sensory neurons to cPGI₂, which increases activation of G_{αs} through the IP receptor; forskolin, which is a direct activator of adenylyl cyclase; or CTX, which ADP-ribosylates G_{αs}, also sensitizes sensory neurons [7]. Consequently, we examined whether these various drug treatments enhance PKA activity in our neuronal cultures. Exposing the cultures to 1 μM PGE₂ increases PKA activity ~ninefold above that seen in vehicle-treated cells (0.01 % MPL; Fig. 1b), whereas 300 nM of the EP4 receptor agonist, L902688, increased PKA activity ~3.5-fold and 1 μM cPGI₂ increased activity ~ninefold (Fig. 1b). Activation of adenylyl cyclases with 1 μM forskolin or exposure of cultures overnight to 1 μM CTX to activate G_{αs} also significantly increased PKA activity ~five- and ~ninefold compared to vehicle, respectively (Fig. 1b). We also examined whether activation of β -adrenergic receptors with isoproterenol would increase PKA activity since this drug when injected into the hindpaw of rats augments nociceptive behaviors [33]. Exposing neuronal cultures to 10 μM isoproterenol produced a small increase in PKA (1.2-fold) above vehicle-treated cultures (Fig. 1b). Although significant, only modest PKA activation was observed following exposure to a range of isoproterenol concentrations (1–100 μM). The ratios of isoproterenol-activated PKA to total PKA activity were 0.12 ± 0.01 , 0.10 ± 0.004 , 0.11 ± 0.01 , 0.13 ± 0.01 , and 0.11 ± 0.003 for 1, 3, 10, 30, and 100 μM , respectively (data not shown).

PGE₂-induced augmentation of capsaicin-evoked iCGRP release is maintained after long-term exposure to the eicosanoid but is not mediated by activation of PKA

Since the acute sensitizing action of PGE₂ on sensory neurons is mediated through activation of EP receptors that are part of the GPCR family [6, 34], chronic exposure to PGE₂ should result in tolerance or desensitization to the sensitizing effects of this prostanoid. Previous studies, however, suggest that the ability of PGE₂ to sensitize sensory neurons does not downregulate after chronic exposure to the eicosanoid [17, 24]. Consequently, we examined whether the ability of PGE₂ to augment capsaicin-evoked release of iCGRP from sensory neurons downregulated after long-term exposure to the prostanoid and whether this sensitizing action was attenuated by the PKA inhibitor, H-89. When sensory neurons in culture were exposed to 30 nM capsaicin, release of iCGRP increased approximately threefold from a basal level of 3.4 ± 0.7 % of total content/10 min to 10.5 ± 1.3 % of total content/10 min (Fig. 2a). Treating cells with 1 μM PGE₂ significantly augmented the capsaicin-evoked release to 15.6 ± 1.4 % of total content/10 min (Fig. 2a). Although exposure to 10 μM H-89 did not alter basal or capsaicin-stimulated release of iCGRP, it did block the ability of PGE₂ to augment capsaicin-evoked release (Fig. 2a).





Fig. 1 Prostaglandin E₂ and other activators of cAMP production increase PKA activity in sensory neuronal cultures. **a** Each point represents mean \pm SEM of PKA activity normalized to total PKA after 10-min exposure to various concentrations of PGE₂ from 4 to 6 independent harvests of cells maintained in the absence of added NGF. Asterisks indicate a statistically significant increase in PKA activity compared to the vehicle-treated control using one-way ANOVA followed by Bonferroni's post hoc test. **b** Each column represents the mean \pm SEM of PKA activity normalized to total PKA after a 10-min exposure to vehicle (V), PGE₂, the EP₄ receptor agonist, L902688, cPGI₂, forskolin, CTX, or isoproterenol (Iso) as indicated. An asterisk indicates a statistically significant difference between PKA activation by each treatment compared to its respective vehicle control using Student's *t* test

To examine the effects of long-term exposure to PGE₂, we treated sensory neuronal cultures with 1 μM PGE₂ for 5 days. For these studies, we replaced the culture media with media containing fresh PGE₂ every 24 h since previous studies demonstrated that PGE₂ levels are maintained after 24 h in culture [35]. When neuronal cultures were treated with 1 μM PGE₂ for 5 days prior to examining iCGRP release and the cells re-exposed to 1 μM PGE₂ for 20 min, the eicosanoid significantly increased the capsaicin-evoked release from a control level of 6.2 ± 0.4 to 11.6 ± 0.6 % of total content/10 min (Fig. 2b) demonstrating that long-term exposure to PGE₂ does not downregulate the sensitizing actions of the prostanoid. Exposing sensory neuronal cultures to 1 μM PGE₂ for 5 days did not alter the total content of iCGRP. Total peptide content in neuronal cultures exposed to vehicle for 5 days was 486 ± 58 fmol/well, whereas in cultures exposed to PGE₂ for 5 days content was 540 ± 67 fmol/well. Thus, using enhancement of iCGRP release as an endpoint of neuronal sensitization, long-term exposure to PGE₂ did not downregulate the sensitizing actions of the prostanoid. Although H-89

prevented the acute sensitizing effects of PGE₂, PGE₂-induced sensitization after long-term exposure to PGE₂ was not blocked by pretreating the cultures with 10 μM H-89 (Fig. 2b). In the presence of 10 μM H-89 alone, capsaicin-evoked release of iCGRP was 8.5 ± 0.7 % of total content/10 min, whereas release from cells treated with 10 μM H-89 and 1 μM PGE₂ was 11.3 ± 0.5 % of total content/10 min. These data support the notion that sensitization of sensory neurons by PGE₂ after chronic exposure to the prostanoid is not dependent on the activation of PKA.

Since PGE₂-induced sensitization is maintained after long-term exposure to the drug (Fig. 2b), and since acute exposure to the eicosanoid increases cAMP production [7], we measured cAMP levels directly to address the question of whether exposing neuronal cultures to 1 μM PGE₂ for 5 days would alter the ability of the prostanoid to augment the production of cAMP. In neuronal cultures exposed to vehicle for 5 days, a 10-min treatment with 1 μM PGE₂ significantly increased the content of cAMP from 68 ± 7 to 183 ± 40 pmol/ml (Fig. 2c). In cultures exposed to 1 μM PGE₂ for 5 days, the content of



cAMP after acute treatment with vehicle was 61 ± 4 pmol/ml and the cAMP content in cells re-exposed to PGE₂ was 76 ± 10 pmol/ml. These values were not significantly different from cAMP content in cells treated with vehicle for 5 days. In contrast, the ability of forskolin to increase cAMP content was not significantly different in cultures exposed for 5 days to vehicle (530 ± 34 pmol/ml) or to 1 μM PGE₂ (501 ± 46 pmol/ml).

Acute PGE₂-induced sensitization and persistent sensitization after long-term exposure to the eicosanoid are mediated by the same EP receptor subtypes

The data presented above suggest that the maintenance of PGE₂ sensitization following chronic exposure to the

prostanoid may be mediated by alternate EP receptors which couple to different G-proteins and activate alternate downstream signaling pathways. To examine this possibility, we measured mRNA for the EP1, EP3C, and EP4 receptors. We chose to study these receptor subtypes since our previous work suggests that EP3C and EP4 receptors contribute to acute sensitization in isolated sensory neurons [6]. Furthermore, acute sensitization by PGE₂ has been proposed to be mediated through activation of EP1 receptors [36]. Six days after harvesting, sensory neuronal cultures were exposed to 1 μM PGE₂ or vehicle for 24 h, and then total RNA was isolated from the treated cells and reverse transcribed to cDNA. Exposing cultures to PGE₂ for 24 h did not significantly alter the

amounts of mRNA for any of the EP receptors examined: EP1, EP3C, and EP4 (Fig. 3a). The levels of mRNA for the EP1 receptor normalized to mRNA for GAPDH were 0.95 ± 0.05 in control cells and 1.10 ± 0.26 after a 24-h treatment with PGE₂. Levels of mRNA for EP3C and EP4 were 0.99 ± 0.14 and 1.11 ± 0.05 in control cells and 0.81 ± 0.07 and 1.03 ± 0.09 , respectively, in cells treated with PGE₂. Similar results were observed from neuronal cultures exposed to PGE₂ for 5 days. In these cultures as in cultures treated for 24 h, long-term exposure to 1 μ M PGE₂ did not significantly alter mRNA to EP1, EP2, EP3, or EP4 receptors compared to cells treated with vehicle for 5 days (data not shown).

We also determined whether a 24 h exposure to PGE₂ would alter the expression of EP receptor proteins using quantitative immunohistochemistry (see the “Methods” section). Analogous to the observations of mRNA expression, long-term exposure of sensory neurons to PGE₂ did not alter EP receptor protein levels (Fig. 3b). The EP1 immunoreactivity in control wells was 84 ± 7 %, whereas immunoreactivity was 74 ± 9 % of the maximal signal after treatment. A 24 h exposure of sensory neurons to PGE₂ did not alter total EP₃ immunoreactivity; the control value of EP3 immunoreactivity was 78 ± 7 %, whereas the EP3 immunoreactivity value was 79 ± 7 % of maximal after a 24 h exposure to PGE₂. Similarly, there was no change in EP4 immunoreactivity. Intensity values for EP4 protein were 83 ± 12 and 87 ± 4 % of maximal in the absence and presence of long-term treatment with PGE₂, respectively (Fig. 3b). Together, the real-time PCR and quantitative immunohistochemistry data suggest that a 24 h exposure of sensory neurons in culture to PGE₂ does not alter the expression of EP receptors.

To identify the EP receptor subtypes that contribute to PGE₂-induced sensitization, we used the selective EP receptor inhibitors ONO-8711, TG4-155, L798,106, and ONO-AE3-208 to block EP1, EP2, EP3, or EP4 receptor subtypes, respectively. In sensory neuronal cultures that were exposed to vehicle for 5 days, pretreating with 30 or 100 nM of the EP2 receptor antagonist, TG4-155; the EP3 receptor antagonist, L798,106; or the EP4 receptor antagonist, ONO-AE3-208, blocked the PGE₂-induced augmentation of capsaicin-stimulated release of iCGRP (Fig. 4a). Exposure to the antagonists in the absence of PGE₂ did not alter basal or capsaicin-stimulated release of iCGRP (Fig. 4a). In contrast, pretreating cultures with the EP1 receptor antagonist, ONO-8711, did not attenuate the PGE₂-induced increase in capsaicin-stimulated





Fig. 3 Twenty-four hour exposure of sensory neurons in culture to 1 μ M PGE₂ does not alter the expression of EP receptors as measured by real-time RT-PCR. **a** Dorsal root ganglia were harvested and cultured for 6 days in media containing 30 ng/ml NGF. After 24-h treatment with vehicle (lightly shaded columns) or 1 μ M PGE₂ (dark-shaded columns), the RNA was isolated and reverse transcribed to cDNA for analysis by PCR. Each column represents the mean \pm SEM of the ratio of EP receptor mRNA to GAPDH mRNA from three independent harvests of cells. **b** Each column represents the mean \pm SEM of the % maximum immunoreactivity for EP receptors normalized to TO-PRO-3 immunoreactivity in neuronal cultures after 24 h treatment with vehicle (lightly shaded columns) or 1 μ M PGE₂ (dark-shaded columns) for six to eight wells of cells



release (Fig. 4a). After 5-day exposure to PGE₂, re-exposure to the prostanoid caused sensitization that was completely inhibited by the EP4 receptor antagonist and to a lesser degree by EP2 and EP3 receptor antagonists, but not by the EP1 receptor antagonist (Fig. 4b). Together, these results show that chronic exposure to PGE₂ does not change the EP receptor profile that mediates sensitization by the eicosanoid.

Long-term exposure to PGE₂ downregulates PKA activity induced by the prostanoid

Although PGE₂-induced sensitization of sensory neurons after long-term exposure to the eicosanoid does not appear to be PKA dependent, the question remains whether the ability of PGE₂ to increase PKA activity downregulates

with chronic exposure to the prostanoid. To examine this directly, we determined whether 1 μM PGE₂ could increase PKA activity in neuronal cultures treated with the eicosanoid for 5 days. As observed in previous experiments, when sensory neuronal cultures were exposed to vehicle for 5 days and then challenged with 1 μM PGE₂ for 10 min, the eicosanoid caused a significant increase in PKA activity from 0.06 ± 0.003 to 0.52 ± 0.1 (Fig. 5a). In contrast, when cultures are exposed to 1 μM PGE₂ for 5 days and then re-exposed to the eicosanoid, there was no significant increase in PKA activity (PKA activity was 0.07 ± 0.0003 , Fig. 5a). Increasing the concentration of PGE₂ 10-fold caused a small, but not significant, increase in PKA activity (0.14 ± 0.01) in cultures exposed to PGE₂ for 5 days (Fig. 5a). The total specific PKA activity after




Fig. 5 Exposing sensory neuronal cultures to PGE₂ or to the EP4 receptor agonist L902688 for 5 days desensitizes the agonist-induced increase in PKA activity. **a** Each column represents the mean ± SEM of the treatment-stimulated PKA activity normalized to total PKA activity from cultures grown in the absence of added NGF and treated with vehicle or PGE₂ (1 μM) for 5 days as indicated. Cultures were washed and then re-exposed for 10 min to vehicle (*open columns*), 1 μM PGE₂ (*closed columns*) or 10 μM PGE₂ (*hatched column*). **b** Each column represents mean ± SEM of total specific activity of PKA after exposure to 10 μM cAMP from cultures treated with vehicle or PGE₂ (1 μM) for 5 days as indicated. Cultures were washed then re-exposed for 10 min to vehicle (*open columns*) or 1 μM PGE₂ (*closed columns*). **c** Each column represents the mean ± SEM of the treatment-stimulated PKA activity normalized to total PKA activity from cultures treated with vehicle, 300 nM L902688, or PGE₂ (1 μM) for 5 days as indicated. Cultures were washed and then re-exposed for 10 min to vehicle (*open columns*) or 300 nM L902688 (*closed columns*). An asterisk indicates a statistically significant difference from vehicle using one-way ANOVA followed by Bonferroni's post hoc test


exposure to 10 μM cAMP was not affected by the long-term exposure to PGE₂ suggesting that the downregulation of PGE₂-activated PKA was not caused by any decrease in the overall kinase activity (Fig. 5b).

Since activation of EP4 receptors on sensory neurons mediates the sensitizing actions of PGE₂ [6, 34], we examined whether long-term exposure to the EP4 receptor agonist L902688 or to PGE₂ downregulated the increase in PKA activity produced by activation of EP4 receptors. We chose to use L902688 in the current experiments because it has an approximate 7000–32,000 higher affinity of binding to EP4 when compared to other EP receptor subtypes [37]. When neuronal cultures were exposed to 300 nM L902688 for 10 min, there was a significant increase in PKA activity from 0.04 ± 0.007 to 0.12 ± 0.01 (Fig. 5c). In contrast, when neuronal cultures were treated with L902688 for 5 days, re-exposure to the agonist did not significantly increase PKA activity above control levels (Fig. 5c). Likewise, when neuronal cultures were treated with 1 μM PGE₂ for 5 days, exposing the cultures to L902688 for 10 min did not increase PKA activity (0.04 ± 0.01 and 0.06 ± 0.01 vehicle and L902688, respectively).

Together, these data suggest that chronic activation of EP4 receptors results in a loss of their ability to couple to PKA signaling in response to an agonist.

Time course of the onset and offset of desensitization of the PGE₂-induced activation of PKA in sensory neuronal cultures after chronic exposure

The data presented above clearly show that exposing sensory neurons to PGE₂ for 5 days abolishes the subsequent PGE₂-induced activation of PKA. To ascertain the duration of exposure to PGE₂ that is necessary to downregulate prostanoinduced activation of PKA and to determine whether this desensitization is reversible, we examined PGE₂-induced PKA activation after cultures were exposed to PGE₂ for various lengths of time. To determine the time course for desensitization, sensory neuronal cultures were exposed to either vehicle for the last 5 days in culture or to 1 μM PGE₂ for the last 3, 6, 12, 72 h or 5 days in culture (Fig. 6a, top panel). In all instances, PKA activity was determined after cells were maintained in culture for 12 days. Three and 6 h exposures of neuronal cultures to PGE₂ resulted in a reduction in the ability of PGE₂ to activate




PKA by approximately 50 % (Fig. 6a). After a 12 h exposure, the PGE₂-induced PKA activity is reduced by 80 %, whereas maximal inhibition is observed after 3 days of exposure (Fig. 6a). To examine whether the desensitization was reversible, sensory neurons in culture were exposed to vehicle for 36 h or to 1 μ M PGE₂ for 36, 33, 24, or 12 h and then to vehicle for 0, 3, 12, or 24 h, respectively (Fig. 6b, top panel), and PKA activity was measured. All cells were maintained in culture for 12 days. Exposure of sensory neurons to 1 μ M PGE₂ for 36 h resulted in desensitization of PGE₂-induced activation of PKA (Fig. 6b), an effect we also observed after 72 h and 5 days of treatment with the eicosanoid (Fig. 6a). Three hours after the PGE₂ is removed, a re-exposure to the eicosanoid did not augment PKA activity (Fig. 6b). In contrast, 12 and 24 h after removal of PGE₂, PKA activation by re-exposure to the eicosanoid recovered to approximately 42 and 78 % of PGE₂-activated PKA in naïve cultures (Fig. 6b). Thus, downregulation of the PGE₂-induced activation of PKA is reversible and not secondary to loss of cell viability after chronic exposure to PGE₂.

Homologous desensitization of PKA signaling after long-term exposure to PGE₂

Classical GPCR desensitization is mediated by receptor uncoupling from the cognate heterotrimeric G-protein and the downstream signaling pathway [13, 38]. Consequently,

in sensory neurons exposed to PGE₂ for 5 days, it is possible that the EP receptors are no longer coupled to the G_{αs}/adenylyl cyclase/PKA pathway. If receptor uncoupling mediates the loss of PGE₂-induced activation of PKA, then bypassing the receptor by directly activating G_{αs} or adenylyl cyclases should increase PKA activity even after long-term exposure to PGE₂. To test this, we examined the effects of CTX or forskolin on PKA activity after long-term exposure of sensory neuronal cultures to PGE₂. When neuronal cultures treated with vehicle for 5 days were exposed to 1.5 μ g/ml CTX overnight, the PKA activity increased from 0.06 ± 0.007 (vehicle) to 0.46 ± 0.01 (Fig. 7a). In a similar manner, when cultures were exposed to PGE₂ for 5 days, CTX increased PKA activity from 0.05 ± 0.003 (vehicle) to 0.46 ± 0.02 (Fig. 7a). When neuronal cultures treated with vehicle for 5 days were exposed to 1 μ M forskolin for 20 min, the activator of adenylyl cyclases significantly increased PKA activity from 0.06 ± 0.01 to 0.28 ± 0.04 (Fig. 7b). In cultures treated with 1 μ M PGE₂ for 5 days, exposure to forskolin increased PKA activity from 0.05 ± 0.01 to 0.27 ± 0.04 (Fig. 7b). Thus, the downregulation of PGE₂-activated PKA appears to result from the uncoupling between PGE₂ and the PKA signaling pathway at the receptor level.

To determine whether the desensitization of the PGE₂-induced PKA activation is heterologous with PGI₂,



we treated sensory neuronal cultures with vehicle or 1 μM PGE₂ for 5 days and examined PKA activity after acute exposure to the stable analog of prostacyclin, cPGI₂ [39]. We chose to examine this eicosanoid since it increases cAMP levels and sensitizes sensory neurons through activation of another GPCR, the IP receptor [7, 40]. In neuronal cultures treated with vehicle for 5 days, a 10-min exposure to 1 μM cPGI₂ significantly increased PKA activity from 0.06 ± 0.004 to 0.544 ± 0.04 . In an analogous manner, cPGI₂ increased the PKA activity from 0.05 ± 0.002 to 0.48 ± 0.05 in neuronal cultures exposed to 1 μM PGE₂ for 5 days (Fig. 7c). These data support the notion that the desensitization observed to PGE₂-induced activation of PKA after long-term administration of the prostanoïd is homologous.

Previous studies have shown that PKA can phosphorylate the β-adrenergic receptor and this can result in desensitization [41]. In an analogous manner, activation of PKC is associated with desensitization of IP receptors [42] and thromboxane receptors [43]. Consequently, after long-term exposure to PGE₂, activation of PKA and/or PKC might result in phosphorylation and uncoupling of the EP receptors from their cognate G-proteins. To examine this, we treated sensory neurons in culture for 12 h with 1 μM PGE₂ in the absence and presence of 10 μM H-89 or 1 μM BIM-I to block PKA or PKC activities, respectively, and then examined the effects of an acute challenge with PGE₂. When neuronal cultures were treated for 12 h with vehicle in the absence or presence of H-89 or BIM-I, exposing the cultures to 1 μM PGE₂ for 10 min

caused a significant (~10-fold) increase in PKA activity compared to cells not exposed to the prostanoid (Fig. 7d). In contrast, in cultures exposed to 1 μM PGE₂ for 12 h in the absence or presence of H-89 or BIM-I, re-exposure to the eicosanoid did not significantly increase PKA activity above basal levels (Fig. 7d). In cultures treated with PGE₂ for 12 h and re-exposed to vehicle, the PKA activity was 0.06 ± 0.01 , whereas with re-exposure to PGE₂, the activity was 0.14 ± 0.02 . In cultures treated with PGE₂ and H-89 or PGE₂ and BIM-I for 12 h, the PKA activity was 0.19 ± 0.02 or 0.16 ± 0.02 after re-exposure to the eicosanoid, respectively (Fig. 7d). These findings suggest that desensitization of the PGE₂-induced activation of PKA after long-term exposure to the prostanoid is not mediated by PKA or PKC-induced phosphorylation of EP receptors.

Acute PGE₂-induced sensitization and persistent sensitization after long-term exposure to the eicosanoid are not mediated by activation of PI3 kinases

The data presented above show that both acute and persistent sensitization of sensory neurons by PGE₂ are mediated by activation of the same EP receptor subtypes but that sensitization after chronic exposure to PGE₂ is not dependent on activation of PKA. Since previous work has shown that binding of PGE₂ to EP4 receptors activates phosphoinositide 3-kinase (PI3K) signaling under different conditions [44] and that inhibiting PI3 kinases attenuates inflammatory pain behaviors [45, 46], we examined whether a pan inhibitor of PI3 kinases would attenuate acute or persistent PGE₂-induced sensitization. In sensory neuronal cultures treated with vehicle for 5 days, exposing

neuronal cultures to 1 or 3 μM LY294002 prior to and throughout exposure to capsaicin did not attenuate the ability of 1 μM PGE₂ to augment stimulated iCGRP release (Fig. 8). In a similar manner, when sensory neurons were treated with 1 μM PGE₂ for 5 days, then re-exposed to PGE₂ neither 1 nor 3 μM LY294002 significantly altered the eicosanoid-induced increase in capsaicin-stimulated release of iCGRP.

Discussion

The results presented here demonstrate for the first time that long-term exposure of sensory neuronal cultures to PGE₂ results in a downregulation in the ability of the eicosanoid to activate PKA. This downregulation occurs rapidly with a significant loss of PKA activation within 3 h of exposure to 1 μM of the agonist and a complete loss within 72 h. Furthermore, it is reversible since within 24 h after removal of PGE₂ from the neuronal cultures, the ability of PGE₂ to increase PKA activity is fully restored. Long-term exposure of neuronal cultures to PGE₂, however, does not diminish total PKA activity in the cells or the ability of CTX, which activates G_{αs} through ADP ribosylation, or forskolin, which activates adenylyl cyclases, to increase PKA activity. Exposing neuronal cultures to the selective EP4 receptor agonist L902688 also activates PKA, and a cross desensitization is observed with this agonist in neuronal cultures exposed to PGE₂ for 5 days. This cross desensitization supports the notion that EP4 receptors are critical mediators of sensitization by PGE₂. This observation is further substantiated by the finding that the EP4 receptor selective antagonist is capable of blocking sensitization caused by acute exposure to PGE₂




Fig. 8 Acute PGE₂-induced sensitization and persistent sensitization after long-term exposure to the eicosanoid are not mediated by activation of PI3 kinases. Each column represents the mean \pm SEM of capsaicin-stimulated release of iCGRP as percent of total iCGRP content per well/10 min in cultures maintained in the absence of added NGF and preexposed to vehicle for 5 days (*left panel*) or to 1 μM PGE₂ for 5 days (*right panel*). After long-term exposure, cultures were acutely exposed to vehicle (*lightly shaded columns*) or to 1 μM PGE₂ (*dark-shaded columns*) for 20 min in the absence or presence of LY294002, as indicated. An *asterisk* indicates a statistically significant difference between capsaicin-stimulated release of iCGRP after vehicle versus after PGE₂ using one-way ANOVA followed by Bonferroni's post hoc test

and by re-exposure to PGE₂ after long-term incubation with the eicosanoid.

The importance of PKA as an effector mediating acute sensitization of sensory neurons induced by PGE₂ is well established. Increasing levels of cAMP in sensory neurons or exposure to cAMP analogs mimics the sensitizing actions of PGE₂ in that the second messenger augments transmitter release from sensory neurons [7], increases the number of action potentials generated by various stimuli [47], sensitizes small unmyelinated sensory fibers to heat [48], increases TRPV1 channel activity [12], increases sodium current in sensory neurons [10, 11], and reduces potassium currents [49]. Inhibitors of PKA block hyperalgesia induced by PGE₂ [50] and attenuate the acute sensitizing actions of PGE₂ on sensory neurons [11, 12, 51, 52]. Although PKA is a critical effector of sensitization in sensory neurons after acute exposure to prostaglandins, it does not appear to be a major effector of persistent sensitization. Exposing the sensory neurons in culture to 1 μM PGE₂ for 5 days does not alter the ability of the prostanoid to augment the capsaicin-stimulated release of the neuropeptide, CGRP from the neurons. With acute exposure to PGE₂, the augmentation of transmitter release is blocked by pretreatment with the PKA inhibitor H-89. This compound has an IC₅₀ for inhibition of PKA in the nanomolar range [53], and at the concentration we used, H-89 completely inhibits PKA activation in our cultures. Unlike the acute sensitizing actions of PGE₂, however, in neurons pretreated with PGE₂ for 5 days, H-89 does not block the sensitizing effects of PGE₂. These data provide a mechanism to account for the observations in animal models that PGE₂-induced sensitization does not downregulate with chronic exposure [54] and that after inflammation or chronic exposure to PGE₂, the hyperalgesia produced by this prostanoid is not blocked by inhibitors of PKA [18, 20, 25].

Long-term exposure to PGE₂ did not downregulate the ability of cPGL₂ to activate PKA in sensory neurons, demonstrating that the PGE₂-induced desensitization is homologous with respect to EP receptors. This finding is somewhat unexpected since both EP and IP receptors are expressed on sensory neurons and PGI₂ produces hyperalgesia [55] and sensitization of sensory neurons through activation of the cAMP transduction cascade in a manner analogous to that of EP receptors [7, 40]. The lack of cross-desensitization, however, suggests that the PGE₂-induced downregulation is not caused by activation of the second messenger-activated kinases, a mechanism which underlies heterologous desensitization [38, 56]. This is consistent with our observations that downregulation of PGE₂-induced activation of PKA is not attenuated in neuronal cultures preexposed to 10 μM H-89 or to 1 μM BIM-I for 12 h during the exposure to PGE₂. This concentration of H-89 is sufficient to totally inhibit PKA activity

in the cultures, as well as the purified catalytic subunit of PKA *in vitro* (data not shown), and blocks the ability of acute PGE₂ to sensitize the neurons. The concentration of BIM-I used in our experiments is sufficient to inhibit activity of classic and novel PKCs [57]. Therefore, it is logical to conclude that neither the two PKA isoforms PKA-I and PKA-II, which are inhibited by H-89 [58, 59], nor the classic or novel PKCs mediate the desensitization induced by long-term exposure to PGE₂.

One interesting observation in the current work is that 10 μM isoproterenol only increases PKA activity modestly compared to 1 μM PGE₂, cPGL₂, forskolin, 1.5 μg/ml cholera toxin, or 300 nM L902688. Moreover, isoproterenol concentrations from 1 to 10 μM did not cause an appreciable difference in PKA activation, suggesting a lack of a concentration-response relationship. One possible explanation for the low levels of PKA activation by isoproterenol is that phosphodiesterase (PDE) activity could increase the breakdown of cAMP in the subcellular compartment in which PKA is localized [60, 61] since we did not include a PDE inhibitor in our assay buffer. Much evidence shows that scaffolding proteins, e.g., A-kinase anchor proteins (AKAPs), can maintain adenylyl cyclase, PKA, and PDE in close proximity, thus creating a highly localized, selective, and controlled signaling complex [62–64] which suggests that breakdown of cAMP could be a variable in controlling PKA activity. It seems unlikely, however, that this could account for the difference in PKA activation by isoproterenol versus PGE₂ since previous reports indicated that activation of PKA by PGE₂ is also subject to PDE suppression via degradation of cAMP [65, 66]. Moreover, PKA activity induced by either PGE₂ (1 μM) or isoproterenol (10 μM) was assayed under the same experimental conditions. Thus, whether PKA-activation is subject to PDE suppression or not, we observed that isoproterenol is at least two orders of magnitude less potent than PGE₂ in activation of PKA in isolated adult rat sensory neuronal cultures.

In the current experiments, we show that exposing the cultures to PGE₂ for 5 days prevents a subsequent treatment with PGE₂ from significantly increasing cAMP levels. This observation confirms previous work [24, 67, 68] and suggests that chronic exposure to PGE₂ causes a downregulation of EP receptors or that the EP receptors are no longer effectively coupled to G_{αs}. However, reduction of EP receptor expression cannot explain the loss of PGE₂-induced cAMP production or PKA activation following long-term exposure to the eicosanoid, since it is evident from our data that neither EP receptor mRNA nor protein was significantly reduced after long-term exposure to PGE₂. It is important to note that increases in cAMP that are sufficient to activate PKA are highly compartmentalized, through interaction with multiple AKAPs [69–71]. Consequently, the measure of total cAMP content in tissues may not reflect the functional effects of the second messenger.

We have previously shown that a 24 h exposure of sensory neuronal cultures to PGE₂ significantly reduces the maximal receptor binding (B_{max}) for the eicosanoid [24]. A similar decrease in B_{max} of PGE₂ occurs in the dorsal spinal cord after inflammation, and this effect is blocked by NSAIDs, suggesting it is secondary to prostaglandin production [24]. These data and our current finding that PKA activation is significantly downregulated after a 12-h exposure to PGE₂ suggest that prolonged exposure to PGE₂ results in downregulation of surface expression of EP receptors, presumably through internalization by the G-protein receptor kinase (GRK) and β-arrestin machinery [72, 73]. Despite the decrease in receptor binding, the ability of PGE₂ to sensitize sensory neurons is not diminished and this is not likely due to a shift from EP receptors linked to G_{αs} to those linked to G_{αq} since a selective EP1 receptor antagonist does not block acute or persistent sensitization by PGE₂. Furthermore, other investigators have shown that inflammation or exposure to PGE₂ results in a modest increase in the expression of EP4 receptors on the plasma membrane in sensory neurons [34, 74, 75], although the reasons for the differences between our results and their findings remain to be determined. Consequently, it is unlikely that changes in receptor expression could account for a loss of the ability of PGE₂ to activate PKA while maintaining the ability to sensitize the neurons. A more likely explanation is that after chronic PGE₂, the signaling pathway mediating PGE₂-induced sensitization switches from G_{αs} to other heterotrimeric G-proteins, such as G_{αq/11}, or G_{α12/13} in a manner analogous to that observed with β-adrenergic receptors [76]. In the case of the EP4 receptors, studies in heterologous expression systems have shown that the receptor can couple to G_{αs} and G_{αi/o} under different conditions [77, 78]. Moreover, there is precedent to suggest that EP4 receptors may signal through G_{βγ} [79, 80]. In both cases, however, it is thought that PI3K relays the signal from either G_{αi/o} or G_{βγ} to downstream signaling pathways [44]. Nevertheless, LY294002 did not attenuate PGE₂-induced sensitization after acute or long-term exposure to the eicosanoid, suggesting that PI3K does not contribute to PGE₂-induced sensitization in sensory neurons.

It remains to be determined how PGE₂ maintains its sensitization after long-term exposure to the eicosanoid. One possibility is that EP receptors, especially EP4, become phosphorylated on the C-terminus by GRKs [81] and that β-arrestins are recruited to EP4 receptors following exposure to PGE₂ [82, 83]. β-arrestin-mediated signaling is well characterized and includes a wide array of signaling pathways [84], including, but not limited to, the MEK/ERK signaling pathway [85]. Thus, activation of as yet, undiscovered downstream signaling cascades might provide a means for sensitization to last after long-term exposure to PGE₂. Further work is warranted to attempt to discover the downstream signaling mediating persistent sensitization

since selective manipulation of such a pathway may prove useful in treating chronic inflammatory pain.

Conclusions

Long-term exposure to PGE₂ does not alter its ability to sensitize sensory neurons; however, the signaling pathway that mediates the sensitizing action of PGE₂ is no longer dependent upon activation of PKA. Indeed, long-term exposure to PGE₂ results in downregulation of the ability of PGE₂ or the EP4 selective agonist, L902688, to activate PKA. This downregulation is reversible and homologous since it does not affect the ability of PGI₂ to activate PKA. PGE₂-induced sensitization after long-term exposure is largely mediated by EP4 receptor and is independent of both PKA and PI3K signaling pathways.

Abbreviations

cAMP, 3',5'-cyclic adenosine monophosphate; cPGI₂, carbaprostacyclin; CTX, cholera toxin; GPCRs, G-protein-coupled receptors; iCGRP, immunoreactive calcitonin gene-related peptide; MPL, 1-methyl-2-pyrrolidinone; NGF, nerve growth factor; PDE, phosphodiesterase; PGE₂, prostaglandin E₂; PGI₂, prostaglandin I₂; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A; PKC, protein kinase C; PKI 5-24, PKA pseudosubstrate inhibitor fragment 5-24

Acknowledgements

We would like to thank Dr. Djane Duarte for assisting with the cAMP assays and Eric Thompson and Chunlu Guo for their expert technical assistance.

Funding

This work was supported by NIH grants NS034159 and NS069915 to MRV and NIH grant NS078171 to AH. Ramy Habashy Malty was partly funded by the Ministry of Higher Education, Cairo, Egypt. These studies were conducted in a facility constructed with the support from Research Facilities Improvement Program Grant Number C06 RR015481-01 from the National Center for Research Resources, National Institutes of Health.

Availability of data and materials

All raw data used in this manuscript are available on request.

Authors' contributions

RHM, AH, and MRV designed the studies. RHM, AH, and JCF performed the various experiments. RHM, JCF, and MRV analyzed the data. All authors contributed to the writing and editing of the manuscript, and all authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval

The Animal Care and Use Committee at Indiana University School of Medicine, Indianapolis, IN, approved all procedures used in these studies. The IACUC protocol identification number is 10818.

Author details

¹Department of Chemistry and Biochemistry, Faculty of Science, University of Regina, Regina, SK, Canada. ²Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA. ³Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA. ⁴Department of Pharmacology and Toxicology, Indiana University School of Medicine, 635 Barnhill Dr., A449, Indianapolis, IN 46202, USA.

Received: 2 February 2016 Accepted: 27 June 2016

Published online: 11 July 2016

References

- Petho G, Reeh PW. Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. *Physiol Rev*. 2012;92(4):1699–775. doi:10.1152/physrev.00048.2010.
- Schaible HG, Ebersberger A, Von Banchet GS. Mechanisms of pain in arthritis. *Ann N Y Acad Sci*. 2002;966:343–54.
- Bombardieri S, Cattani P, Ciabattini G, Di Munno O, Pasero G, Patrono C, et al. The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and nonsteroidal anti-inflammatory drugs. *Br J Pharmacol*. 1981;73(4):893–901.
- Opas EE, Dallob A, Herold E, Luell S, Humes JL. Pharmacological modulation of eicosanoid levels and hyperalgesia in yeast-induced inflammation. *Biochem Pharmacol*. 1987;36(4):547–51.
- Kidd BL, Urban LA. Mechanisms of inflammatory pain. *Br J Anaesth*. 2001;87(1):3–11.
- Southall MD, Vasko MR. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. *J Biol Chem*. 2001;276(19):16083–91. doi:10.1074/jbc.M011408200.
- Hingtgen CM, Waite KJ, Vasko MR. Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3',5'-cyclic monophosphate transduction cascade. *J Neurosci*. 1995;15(7 Pt 2):5411–9.
- Wise H. Lack of interaction between prostaglandin E2 receptor subtypes in regulating adenyl cyclase activity in cultured rat dorsal root ganglion cells. *Eur J Pharmacol*. 2006;535(1–3):69–77. doi:10.1016/j.ejphar.2006.02.018.
- Taiwo YO, Levine JD, Burch RM, Woo JE, Mobley WC. Hyperalgesia induced in the rat by the amino-terminal octapeptide of nerve growth factor. *Proc Natl Acad Sci U S A*. 1991;88(12):5144–8.
- Gold MS, Reichling DB, Shuster MJ, Levine JD. Hyperalgesic agents increase a tetrodotoxin-resistant Na⁺ current in nociceptors. *Proc Natl Acad Sci U S A*. 1996;93(3):1108–12.
- England S, Bevan S, Docherty RJ. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurons via the cyclic AMP-protein kinase A cascade. *J Physiol*. 1996;495(Pt 2):429–40.
- Lopshire JC, Nicol GD. The cAMP transduction cascade mediates the prostaglandin E2 enhancement of the capsaicin-elicited current in rat sensory neurons: whole-cell and single-channel studies. *J Neurosci*. 1998;18(16):6081–92.
- Sibley DR, Lefkowitz RJ. Molecular mechanisms of receptor desensitization using the beta-adrenergic receptor-coupled adenylate cyclase system as a model. *Nature*. 1985;317(6033):124–9.
- Sibley DR, Benovic JL, Caron MG, Lefkowitz RJ. Phosphorylation of cell surface receptors: a mechanism for regulating signal transduction pathways. *Endocr Rev*. 1988;9(1):38–56. doi:10.1210/edrv-9-1-38.
- Lanas A. Clinical experience with cyclooxygenase-2 inhibitors. *Rheumatology (Oxford)*. 2002;41(Suppl 1):16–22. discussion 35–42.
- O'Dell JR. Therapeutic strategies for rheumatoid arthritis. *N Engl J Med*. 2004;350(25):2591–602. doi:10.1056/NEJMra040226.
- Shah S, Mehta V. Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management. *Postgrad Med J*. 2012;88(1036):73–8. doi:10.1136/postgradmedj-2011-130291.
- Villarreal CF, Sachs D, Funez MI, Parada CA, de Queiroz CF, Ferreira SH. The peripheral pro-nociceptive state induced by repetitive inflammatory stimuli involves continuous activation of protein kinase A and protein kinase C epsilon and its Na(V)1.8 sodium channel functional regulation in the primary sensory neuron. *Biochem Pharmacol*. 2009;77(5):867–77. doi:10.1016/j.bcp.2008.11.015.
- Eijkelkamp N, Heijnen CJ, Willemsen HL, Deumens R, Joosten EA, Kleibeuker W, et al. GRK2: a novel cell-specific regulator of severity and duration of inflammatory pain. *J Neurosci*. 2010;30(6):2138–49. doi:10.1523/JNEUROSCI.5752-09.2010.
- Parada CA, Reichling DB, Levine JD. Chronic hyperalgesic priming in the rat involves a novel interaction between cAMP and PKCepsilon second messenger pathways. *Pain*. 2005;113(1–2):185–90. doi:10.1016/j.pain.2004.10.021.
- Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. *Trends Neurosci*. 2009;32(12):611–8. doi:10.1016/j.tins.2009.07.007.
- Lopshire JC, Nicol GD. Activation and recovery of the PGE2-mediated sensitization of the capsaicin response in rat sensory neurons. *J Neurophysiol*. 1997;78(6):3154–64.
- Bolyard LA, Van Looy JW, Vasko MR. Sensitization of rat sensory neurons by chronic exposure to forskolin or 'inflammatory cocktail' does not downregulate and requires continuous exposure. *Pain*. 2000;88(3):277–85.
- Southall MD, Bolyard LA, Vasko MR. Twenty-four hour exposure to prostaglandin downregulates prostanoid receptor binding but does not alter PGE2-mediated sensitization of rat sensory neurons. *Pain*. 2002;96(3):285–96.
- Aley KO, Messing RO, Mochly-Rosen D, Levine JD. Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isoform of protein kinase C. *J Neurosci*. 2000;20(12):4680–5.
- Wang C, Gu Y, Li GW, Huang LY. A critical role of the cAMP sensor Epac in switching protein kinase signalling in prostaglandin E2-induced potentiation of P2X3 receptor currents in inflamed rats. *J Physiol*. 2007;584(Pt 1):191–203. doi:10.1113/jphysiol.2007.135616.
- Vasko MR, Habashy M, Guo C, Duarte DB, Zhang Y, Nicol GD. Nerve growth factor mediates a switch in intracellular signaling for PGE2-induced sensitization of sensory neurons from protein kinase A to Epac. *PLoS One*. 2014;9(8), e104529. doi:10.1371/journal.pone.0104529.
- Burkey TH, Hingtgen CM, Vasko MR. Isolation and culture of sensory neurons from the dorsal-root ganglia of embryonic or adult rats. *Methods Mol Med*. 2004;99:189–202. doi:10.1385/1-59259-770-X:189.
- Chen JJ, Barber LA, Dymshitz J, Vasko MR. Peptidase inhibitors improve recovery of substance P and calcitonin gene-related peptide release from rat spinal cord slices. *Peptides*. 1996;17(1):31–7.
- Demaille JG, Ferraz C, Fischer EH. The protein inhibitor of adenosine 3',5'-monophosphate-dependent protein kinases. The NH2-terminal portion of the peptide chain contains the inhibitory site. *Biochim Biophys Acta*. 1979;586(2):374–83.
- Kemp BE, Graves DJ, Benjamini E, Krebs EG. Role of multiple basic residues in determining the substrate specificity of cyclic AMP-dependent protein kinase. *J Biol Chem*. 1977;252(14):4888–94.
- Aley KO, Levine JD. Role of protein kinase A in the maintenance of inflammatory pain. *J Neurosci*. 1999;19(6):2181–6.
- Levine JD,Coderre TJ, Helms S, Basbaum AI. Beta 2-adrenergic mechanisms in experimental arthritis. *Proc Natl Acad Sci U S A*. 1988;85(12):4553–6.
- Lin CR, Amaya F, Barrett L, Wang H, Takada J, Samad TA, et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. *J Pharmacol Exp Ther*. 2006;319(3):1096–103. doi:10.1124/jpet.106.105569.
- Nirodi CS, Crews BC, Kozak KR, Morrow JD, Marnett LJ. The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells. *Proc Natl Acad Sci U S A*. 2004;101(7):1840–5. doi:10.1073/pnas.0303950101.
- Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. *Mol Pain*. 2005;1:3. doi:10.1186/1744-8069-1-3.
- Young RNBX, Han YX, Slipetz DA, Chaurat N, Belley M, Metters K, Mathieu MC, Greig GM, Denis D, Girard M. Discovery and synthesis of a potent, selective and orally available EP4 receptor agonist. *Heterocycles*. 2004;64:437–46.
- Lefkowitz RJ, Stadel JM, Caron MG. Adenylate cyclase-coupled beta-adrenergic receptors: structure and mechanisms of activation and desensitization. *Annu Rev Biochem*. 1983;52:159–86. doi:10.1146/annurev.bi.52.070183.001111.
- Whittle BJ, Moncada S, Whiting F, Vane JR. Carbacyclin—a potent stable prostacyclin analogue for the inhibition of platelet aggregation. *Prostaglandins*. 1980;19(4):605–27.
- Hingtgen CM, Vasko MR. Prostacyclin enhances the evoked-release of substance P and calcitonin gene-related peptide from rat sensory neurons. *Brain Res*. 1994;655(1–2):51–60.
- Benovic JL, Pike LJ, Cerione RA, Staniszewski C, Yoshimasa T, Codina J, et al. Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. *J Biol Chem*. 1985;260(11):7094–101.
- Schemmuly RT, Pullamsetti SS, Breitenbach SC, Weissmann N, Ghofrani HA, Grimminger F, et al. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. *Respir Res*. 2007;8:4. doi:10.1186/1465-9921-8-4.
- Kelley-Hickie LP, Kinsella BT. EP1- and FP-mediated cross-desensitization of the alpha (alpha) and beta (beta) isoforms of the human thromboxane A2 receptor. *Br J Pharmacol*. 2004;142(1):203–21. doi:10.1038/sj.bjp.0705695.

44. Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. *Pharmacol Rev*. 2013;65(3):1010–52. doi:10.1124/pr.112.007195.
45. Sun RQ, Tu YJ, Yan JY, Willis WD. Activation of protein kinase B/Akt signaling pathway contributes to mechanical hypersensitivity induced by capsaicin. *Pain*. 2006;120(1–2):86–96. doi:10.1016/j.pain.2005.10.017.
46. Leinders M, Koehn FJ, Bartok B, Boyle DL, Shubayev V, Kalcheva I, et al. Differential distribution of PI3K isoforms in spinal cord and dorsal root ganglia: potential roles in acute inflammatory pain. *Pain*. 2014;155(6):1150–60. doi:10.1016/j.pain.2014.03.003.
47. Cui M, Nicol GD. Cyclic AMP mediates the prostaglandin E2-induced potentiation of bradykinin excitation in rat sensory neurons. *Neuroscience*. 1995;66(2):459–66.
48. Kress M, Rodl J, Reeh PW. Stable analogues of cyclic AMP but not cyclic GMP sensitize unmyelinated primary afferents in rat skin to heat stimulation but not to inflammatory mediators, in vitro. *Neuroscience*. 1996;74(2):609–17.
49. Evans AR, Vasko MR, Nicol GD. The cAMP transduction cascade mediates the PGE2-induced inhibition of potassium currents in rat sensory neurons. *J Physiol*. 1999;516(Pt 1):163–78.
50. Taiwo YO, Levine JD. Further confirmation of the role of adenylyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. *Neuroscience*. 1991;44(1):131–5.
51. Burgess GM, Mullaney I, McNeill M, Dunn PM, Rang HP. Second messengers involved in the mechanism of action of bradykinin in sensory neurons in culture. *J Neurosci*. 1989;9(9):3314–25.
52. Smith JA, Davis CL, Burgess GM. Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A. *Eur J Neurosci*. 2000;12(9):3250–8.
53. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. *J Biol Chem*. 1990;265(9):5267–72.
54. Ferreira SH, Lorenzetti BB, De Campos DI. Induction, blockade and restoration of a persistent hypersensitive state. *Pain*. 1990;42(3):365–71.
55. Ferreira SH, Nakamura M, de Abreu Castro MS. The hyperalgesic effects of prostacyclin and prostaglandin E2. *Prostaglandins*. 1978;16(1):31–7.
56. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. *Annu Rev Physiol*. 2007;69:511–34. doi:10.1146/annurev.physiol.69.022405.154731.
57. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. *J Biol Chem*. 1991;266(24):15771–81.
58. Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. *Annu Rev Biochem*. 1990;59:971–1005. doi:10.1146/annurev.bi.59.070190.004543.
59. Isensee J, Diskar M, Waldherr S, Buschow R, Hasenauer J, Prinz A, et al. Pain modulators regulate the dynamics of PKA-Ril phosphoorylation in subgroups of sensory neurons. *J Cell Sci*. 2014;127(Pt 1):216–29. doi:10.1242/jcs.136580.
60. Yang JH, Polanowska-Grabowska RK, Smith JS, Shields CW, Saucerman JJ. PKA catalytic subunit compartmentation regulates contractile and hypertrophic responses to beta-adrenergic signaling. *J Mol Cell Cardiol*. 2014;66:83–93. doi:10.1016/j.yjmcc.2013.11.001.
61. Yaniv Y, Ganesan A, Yang D, Ziman BD, Lyashkov AE, Levchenko A, et al. Real-time relationship between PKA biochemical signal network dynamics and increased action potential firing rate in heart pacemaker cells: kinetics of PKA activation in heart pacemaker cells. *J Mol Cell Cardiol*. 2015;86:168–78. doi:10.1016/j.yjmcc.2015.07.024.
62. Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, Kapiloff MS, et al. The protein kinase A anchoring protein mAkap coordinates two integrated cAMP effector pathways. *Nature*. 2005;437(7058):574–8. doi:10.1038/nature03966.
63. Gervasi N, Tchenio P, Preat T. PKA dynamics in a drosophila learning center: coincidence detection by rutabaga adenylyl cyclase and spatial regulation by dunce phosphodiesterase. *Neuron*. 2010;65(4):516–29. doi:10.1016/j.neuron.2010.01.014.
64. Willoughby D, Wong W, Schaack J, Scott JD, Cooper DM. An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. *EMBO J*. 2006;25(10):2051–61. doi:10.1038/sj.emboj.7601113.
65. Ikari J, Michalski JM, Iwasawa S, Gunji Y, Nogel S, Park JH, et al. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2. *Am J Respir Cell Mol Biol*. 2013;49(4):571–81. doi:10.1165/rcmb.2013-0004OC.
66. Cunha FQ, Teixeira MM, Ferreira SH. Pharmacological modulation of secondary mediator systems—cyclic AMP and cyclic GMP—on inflammatory hyperalgesia. *Br J Pharmacol*. 1999;127(3):671–8. doi:10.1038/sj.bjp.0702601.
67. Rowlands DK, Kao C, Wise H. Regulation of prostacyclin and prostaglandin E(2) receptor mediated responses in adult rat dorsal root ganglion cells, in vitro. *Br J Pharmacol*. 2001;133(1):13–22. doi:10.1038/sj.bjp.0704028.
68. Sachs D, Villarreal C, Cunha F, Parada C, Ferreira S. The role of PKA and PKCepsilon pathways in prostaglandin E2-mediated hypernociception. *Br J Pharmacol*. 2009;156(5):826–34. doi:10.1111/j.1476-5381.2008.00093.x.
69. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. *Physiol Rev*. 2004;84(1):137–67. doi:10.1152/physrev.00021.2003.
70. Beene DL, Scott JD. A-kinase anchoring proteins take shape. *Curr Opin Cell Biol*. 2007;19(2):192–8. doi:10.1016/j.ccb.2007.02.011.
71. Welch EJ, Jones BW, Scott JD. Networking with AKAPs: context-dependent regulation of anchored enzymes. *Mol Interv*. 2010;10(2):86–97. doi:10.1124/mi.10.2.6.
72. Desai S, April H, Nwaneshiudu C, Ashby B. Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. *Mol Pharmacol*. 2000;58(6):1279–86.
73. Penn RB, Pascual RM, Kim YM, Mundell SJ, Krymskaya VP, Panettieri Jr RA, et al. Arrestin specificity for G protein-coupled receptors in human airway smooth muscle. *J Biol Chem*. 2001;276(35):32648–56. doi:10.1074/jbc.M104143200.
74. St-Jacques B, Ma W. Prostaglandin E2/EP4 signalling facilitates EP4 receptor externalization in primary sensory neurons in vitro and in vivo. *Pain*. 2013;154(2):313–23. doi:10.1016/j.pain.2012.11.005.
75. St-Jacques B, Ma W. Peripheral prostaglandin E2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors. *Exp Neurol*. 2014;261:354–66. doi:10.1016/j.expneurol.2014.05.028.
76. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. *Nature*. 1997;390(6655):88–91. doi:10.1038/36362.
77. Fujino H, Regan JW. EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. *Mol Pharmacol*. 2006;69(1):5–10. doi:10.1124/mol.105.017749.
78. Neuschafer-Rube F, Hanecke K, Blaschke V, Jungermann K, Puschel GP. The C-terminal domain of the Gs-coupled EP4 receptor confers agonist-dependent coupling control to Gi but no coupling to Gs in a receptor hybrid with the Gi-coupled EP3 receptor. *FEBS Lett*. 1997;401(2–3):185–90.
79. Thomason PA, James SR, Casey PJ, Downes CP. A G-protein beta gamma-subunit-responsive phosphoinositide 3-kinase activity in human platelet cytosol. *J Biol Chem*. 1994;269(24):16525–8.
80. Hazeki O, Okada T, Kurosu H, Takasuga S, Suzuki T, Katada T. Activation of PI 3-kinase by G protein betagamma subunits. *Life Sci*. 1998;62(17–18):1555–9.
81. Nishigaki N, Negishi M, Ichikawa A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. *Mol Pharmacol*. 1996;50(4):1031–7.
82. Leduc M, Breton B, Gales C, Le Gouill C, Bouvier M, Chemtob S, et al. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. *J Pharmacol Exp Ther*. 2009;331(1):297–307. doi:10.1124/jpet.109.156398.
83. Neuschafer-Rube F, Hermosilla R, Rehwald M, Ronnstrand L, Schulein R, Wernstedt C, et al. Identification of a Ser/Thr cluster in the C-terminal domain of the human prostaglandin receptor EP4 that is essential for agonist-induced beta-arrestin1 recruitment but differs from the apparent principal phosphorylation site. *Biochem J*. 2004;379(Pt 3):573–85. doi:10.1042/BJ20031820.
84. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. *Pharmacol Rev*. 2010;62(2):305–30. doi:10.1124/pr.109.002436.
85. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. *Annu Rev Physiol*. 2007;69:483–510. doi:10.1146/annurev.ph.69.013107.100021.